No more delays: Blue Jays call up top prospect Brett Lawrie

42 Comments

Brett Lawrie was on the verge of being called up in May when a broken hand knocked him out for two months, but he’s hit .350 at Triple-A since returning in mid-July and today the Blue Jays officially added their top prospect to the roster.

There are questions about whether Lawrie can stick at third base defensively long term, but he’ll get a chance to play the hot corner for now with Jose Bautista shifting back to right field and his bat is the real draw anyway.

Lawrie, who was acquired from the Brewers for Shaun Marcum this winter, hit .353 with 18 homers and a 1.076 OPS in 69 total games at Triple-A, which is pretty damn impressive for a 21-year-old even at hitter-friendly Las Vegas in the hitter-friendly Pacific Coast League.

He didn’t show nearly that much pop at Double-A last season, hitting .285 with eight homers in 135 games, but the 16th overall pick in the 2008 draft ranked 10th on Baseball America‘s midseason top prospect list with the only position players ahead of him being Bryce Harper, Mike Trout, Manny Machado, and Jesus Montero.

To make room for Lawrie in the lineup and Bautista in the outfield the Blue Jays demoted Travis Snider to Triple-A for the second time this season. Snider was once a very highly touted prospect himself, but he’s struggled to make consistent contact or control the strike zone. So far a .249 batting average and .308 on-base percentage have offset Snider’s significant power potential, but he’s also still just 23 years old.

MLB, union resume blood testing after pandemic, lockout

Scott Taetsch-USA TODAY Sports
1 Comment

NEW YORK – In the first acknowledgment that MLB and the players’ association resumed blood testing for human growth hormone, the organizations said none of the 1,027 samples taken during the 2022 season tested positive.

HGH testing stopped in 2021 because of the COVID-19 pandemic. Testing also was halted during the 99-day lockout that ended in mid-March, and there were supply chain issues due to COVID-19 and additional caution in testing due to coronavirus protocols.

The annual public report is issued by Thomas M. Martin, independent program administrator of MLB’s joint drug prevention and treatment program. In an announcement accompanying Thursday’s report, MLB and the union said test processing is moving form the INRS Laboratory in Quebec, Canada, to the UCLA Laboratory in California.

MLB tests for HGH using dried blood spot testing, which was a change that was agreed to during bargaining last winter. There were far fewer samples taken in 2022 compared to 2019, when there were 2,287 samples were collected – none positive.

Beyond HGH testing, 9,011 urine samples were collected in the year ending with the 2022 World Series, up from 8,436 in the previous year but down from 9,332 in 2019. And therapeutic use exemptions for attention deficit hyperactivity disorder dropped for the ninth straight year, with just 72 exemptions in 2022.

Overall, the league issued six suspensions in 2022 for performance-enhancing substances: three for Boldenone (outfielder/first baseman Danny Santana, pitcher Richard Rodriguez and infielder Jose Rondon, all free agents, for 80 games apiece); one each for Clomiphene (Milwaukee catcher Pedro Severino for 80 games), Clostebol (San Diego shortstop Fernando Tatis Jr. for 80 games) and Stanozolol (Milwaukee pitcher J.C. Mejia for 80 games).

There was an additional positive test for the banned stimulant Clobenzorex. A first positive test for a banned stimulant results in follow-up testing with no suspension.